{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.3","upperLimit":"52.4","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"ORR for MDS cohort is defined as the percentage of participants achieving Complete Response (CR), Marrow CR, CRp (as per CR but platelet count \\<100 x 10\\^9 cells/Liter\\[L\\]), CRi (as per CR but platelet count \\<100 x 10\\^9cells/L or neutrophil count \\<1 x 10\\^9 cells/L), or Partial Response (PR) per response criteria. Complete response is defined as bone marrow \\<=5% myeloblasts with normal maturation of all cell lines, with hemoglobin concentration of \\>=11 grams per deciliter (g/dL), absolute neutrophil count \\>=1 x 10\\^9 cells/L, platelet count \\>=100x10\\^9 cells/L and 0% blasts in the peripheral blood. Marrow CR is defined as Bone marrow \\<=5% myeloblasts and decrease by \\>=50% over pre-treatment. Objective response rate was determined by the investigator according to international myeloma working group (IMWG) response criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 75 mg QD MDS"}],"paramType":"NUMBER","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Up to 36.4 weeks","title":"Part 2: Objective Response Rate (ORR) (MDS Cohort)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}